Clinical Trial

OPtimal Adult Heart Transplant Immunosuppression With MicroRNA Levels

Study acronym: OPTIMAL
Recruiting
View on ClinicalTrials.gov →
Summary
This study aims to develop and refine a microRNA (miR) biomarker panel that can be used to phenotype net immune state after heart transplantation using circulating miRs (associated with drug doses and levels). These miRs will be used to characterize the overall immune state in adult heart transplant patients and predict patients that will go on to develop infection and rejection. MicroRNAs (miRs) are small, non-coding RNA molecules that regulate gene expression and serve as molecular biomarkers found in the circulation.
Protocol Amendment History 1 change
notable Sponsor changed: Inova Health Care Services -> Northwestern University 2026-08-12
Trial Details
NCT Number NCT06939751
Lead Sponsor Northwestern University
Collaborators: National Heart, Lung, and Blood Institute (NHLBI)
Conditions Cardiac Failure, Graft Rejection
Enrollment 250 participants
Start Date 2025-10-28
Primary Completion 2031-01-01 (estimated)
Study Completion 2032-01-01 (estimated)
Updated on ClinicalTrials.gov 2026-08-11